| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative … RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ... The lancet oncology 16 (1), 25-35, 2015 | 2103 | 2015 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 298 | 2021 |
| Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups … RS Finn, JP Crown, J Ettl, M Schmidt, IM Bondarenko, I Lang, T Pinter, ... Breast Cancer Research 18, 1-14, 2016 | 195 | 2016 |
| Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced … RS Finn, K Boer, I Bondarenko, R Patel, T Pinter, M Schmidt, YV Shparyk, ... Breast cancer research and treatment 183, 419-428, 2020 | 193* | 2020 |
| New drug development RS Finn, JP Crown, K Boer, I Lang, RJ Parikh, A Breazna, SN Ho, ST Kim, ... Annals of Oncology-English Edition 23 (2), ii43, 2012 | 164 | 2012 |
| A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with … J Bennouna, I Lang, M Valladares-Ayerbes, K Boer, A Adenis, P Escudero, ... Investigational new drugs 29, 1021-1028, 2011 | 161 | 2011 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI … C Saura, D Hlauschek, M Oliveira, D Zardavas, A Jallitsch-Halper, ... The Lancet Oncology 20 (9), 1226-1238, 2019 | 98 | 2019 |
| Fulvestrant in advanced breast cancer: evidence to date and place in therapy K Boér Therapeutic advances in medical oncology 9 (7), 465-479, 2017 | 71 | 2017 |
| Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line … RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ... Cancer Research 74 (19), 2014 | 70 | 2014 |
| Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine K Boer, E Helinger, A Helinger, P Pocza, Z Pos, P Demeter, Z Baranyai, ... European journal of cell biology 87 (4), 227-236, 2008 | 62 | 2008 |
| Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study K Boér, I Láng, A Llombart-Cussac, I Andreasson, GL Vivanco, N Sanders, ... Investigational new drugs 30, 681-687, 2012 | 52 | 2012 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 45 | 2021 |
| Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC)—a Hungarian experience in the BCIRG 001 trial K Boér, I L↭ g, É Juhos, T Pintér, J Szántó Pathology Oncology Research 9, 166-169, 2003 | 31 | 2003 |
| Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients … C Saura, E De Azambuja, D Hlauschek, M Oliveira, D Zardavas, ... Annals of Oncology 28, v605, 2017 | 27 | 2017 |
| Primary results of LORELEI: a phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients … C Saura, E De Azambuja, D Hlauschek, M Oliveira, D Zardavas, ... Annals of Oncology 28, v605, 2017 | 27 | 2017 |
| Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis KA Gelmon, PA Fasching, FJ Couch, J Balmaña, S Delaloge, ... European Journal of Cancer 152, 68-77, 2021 | 26 | 2021 |
| Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer K Boér OncoTargets and therapy, 6119-6125, 2016 | 22 | 2016 |
| Effective treatment strategy in elderly breast cancer patients K Boér Orvosi Hetilap 146 (1), 15-21, 2005 | 20 | 2005 |
